Category - Markets

Beacon Securities initiated coverage of Profound Medical (TSXV:PRN) with a “buy” rating and 12-month price target of $3.10. The stock closed at $1 on Feb. 28. “We believe Profound Medical is a company who is building...

Ladenburg Thalmann raised its price target for Novavax (NASDAQ:NVAX) to $3.50 from $2.50 after the company presented Phase 1/2 data suggesting its NanoFlu vaccine has the potential to be the most potent product for...

Roth Capital Partners launched coverage of Acer Therapeutics (NASDAQ:ACER) with a “buy” rating and price target of $70. The stock closed at $17.28 on Feb. 23. Acer’s focuses on vascular Ehlers-Danlos Syndromes (vEDS), a...

Roth Capital Partners launched coverage of ArQule (NASDAQ:ARQL) with a “buy” rating and $5 price target. The stock closed at $1.67 on Feb. 21. “We believe that the value-driving components of the pipeline have been in...

Stifel upgraded Momenta Pharmaceuticals (NASDAQ:MNTA) to “buy” from “hold” and raised its price target to $21 from $18. The stock closed at $16.35 on Feb. 21. “As part of our stock call, we acknowledge two opposing...

Roth Capital Partners initiated coverage of Anthera Pharmaceuticals (NASDAQ:ANTH) with a “buy” rating and $10 price target. The stock closed at $1.69 on Feb. 20. The company’s value driver, Sollpura, is an oral...

Analysts for Ladenburg Thalmann and Roth Capital Partners initiated coverage of Eyenovia (NASDAQ:EYEN) with “buy” ratings and price targets of $35 and $20, respectively. The stock closed at $9 on Feb. 16. Eyenovia...

Leerink launched coverage of resTORbio (NASDAQ:TORC) with an “outperform” rating and $36 price target. The stock closed at $18.76 on Feb. 16. “Our rating and valuation are based on our sales forecast for lead asset...

Leerink initiated coverage of Solid Biosciences (NASDAQ:SLDB) with an “outperform” rating and $36 price target. The stock closed at $24.93 on Feb. 16. “We are encouraged by the preclinical data generated for...

William Blair launched coverage of Acer Therapeutics (NASDAQ:ACER) with an “outperform” rating and fair value estimate of $47. The stock closed at $17 on Feb. 15. Acer is developing two late-stage clinical...